Coherus BioSciences Q1 2024 Adj EPS $(0.32) Misses $(0.24) Estimate, Sales $77.063M Miss $80.248M Estimate
Portfolio Pulse from Benzinga Newsdesk
Coherus BioSciences (NASDAQ:CHRS) reported Q1 2024 adjusted EPS of $(0.32), missing the $(0.24) estimate, and sales of $77.063M, missing the $80.248M estimate. Despite the miss, this represents a significant improvement over the previous year, with a 57.33% decrease in losses per share and a 137.58% increase in sales.
May 09, 2024 | 9:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Coherus BioSciences reported a Q1 2024 adjusted EPS of $(0.32), missing estimates, and sales of $77.063M, also below expectations. However, the company showed significant improvement compared to the previous year.
Missing both EPS and sales estimates can negatively impact investor sentiment and stock price in the short term. However, the significant year-over-year improvement in both losses per share and sales growth may mitigate some negative sentiment.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100